




RealRate

PHARMACEUTICAL 2020

Evoke Pharma Inc
Rank 230 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Evoke Pharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 195%, being 43% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	6,246
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,015
Liabilities, Non-Current	0
Other Assets	150
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	29
Other Revenues	0
Property and Equipment	0
Research and Development	3,416
Selling, General and Administrative Expense	3,738

Output Variable	Value in 1000 USD
Assets	6,396
Liabilities	2,015
Expenses	7,154
Revenues	0
Stockholders Equity	4,381
Net Income	-7,126
Comprehensive Net Income	-7,126
BaseVar	7,797
ECR before Limited Liability	58%
Economic Capital Ratio	195%